Fei Hong

Fei Hong has over 15 years of experience in the biotechnology industry. Fei began their career in 2005 as a Postdoctoral Research Fellow at GNF. In 2007, they joined aTyr Pharma as a Scientist, Analytical and Formulation Development and Head of Mass Spectrometry. During their time at aTyr Pharma, they led the analytical and formulation efforts in the discovery and development of biological therapeutics Resolaris and Stalaris. In 2015, they became the Group Leader, Head of Analytical and Formulation Development at Ambrx, Inc. where they were responsible for the development of ARX788, a clinical stage biotechnology product. In 2019, they joined Evofem Biosciences as Director, Head of CMC Development and Regulatory. Most recently, in 2020, they became Director, Pharmaceutical Product Development at Beloteca, Inc. and in 2021, they were appointed Vice President, Head of CMC at Cellics Therapeutics, Inc.

Fei Hong obtained a PhD in pharmaceutical sciences from the University of Arizona between 2001 and 2005.